Atorvastatin for Anthracycline-Associated Cardiac Dysfunction

医学 蒽环类 阿托伐他汀 射血分数 内科学 随机对照试验 化疗 队列 回顾性队列研究 心力衰竭 癌症 乳腺癌
作者
Tomas G. Neilan,Thiago Quinaglia,Takeshi Onoue,Syed Mahmood,Zsófia D. Drobni,Hannah Gilman,Amanda M. Smith,Julius C. Heemelaar,Priya Brahmbhatt,Jor Sam Ho,Supraja Sama,Jakub Svoboda,Donna Neuberg,Jeremy S. Abramson,Ephraim P. Hochberg,Jefferey A. Barnes,Philippe Armand,Eric D. Jacobsen,Caron A. Jacobson,Austin I. Kim
出处
期刊:JAMA [American Medical Association]
卷期号:330 (6): 528-528 被引量:84
标识
DOI:10.1001/jama.2023.11887
摘要

Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with a reduction in cardiac dysfunction due to anthracycline use. Objective To test whether atorvastatin is associated with a reduction in the proportion of patients with lymphoma receiving anthracyclines who develop cardiac dysfunction. Design, Setting, and Participants Double-blind randomized clinical trial conducted at 9 academic medical centers in the US and Canada among 300 patients with lymphoma who were scheduled to receive anthracycline-based chemotherapy. Enrollment occurred between January 25, 2017, and September 10, 2021, with final follow-up on October 10, 2022. Interventions Participants were randomized to receive atorvastatin, 40 mg/d (n = 150), or placebo (n = 150) for 12 months. Main Outcomes and Measures The primary outcome was the proportion of participants with an absolute decline in left ventricular ejection fraction (LVEF) of ≥10% from prior to chemotherapy to a final value of <55% over 12 months. A secondary outcome was the proportion of participants with an absolute decline in LVEF of ≥5% from prior to chemotherapy to a final value of <55% over 12 months. Results Of the 300 participants randomized (mean age, 50 [SD, 17] years; 142 women [47%]), 286 (95%) completed the trial. Among the entire cohort, the baseline mean LVEF was 63% (SD, 4.6%) and the follow-up LVEF was 58% (SD, 5.7%). Study drug adherence was noted in 91% of participants. At 12-month follow-up, 46 (15%) had a decline in LVEF of 10% or greater from prior to chemotherapy to a final value of less than 55%. The incidence of the primary end point was 9% (13/150) in the atorvastatin group and 22% (33/150) in the placebo group ( P = .002). The odds of a 10% or greater decline in LVEF to a final value of less than 55% after anthracycline treatment was almost 3 times greater for participants randomized to placebo compared with those randomized to atorvastatin (odds ratio, 2.9; 95% CI, 1.4-6.4). Compared with placebo, atorvastatin also reduced the incidence of the secondary end point (13% vs 29%; P = .001). There were 13 adjudicated heart failure events (4%) over 24 months of follow-up. There was no difference in the rates of incident heart failure between study groups (3% with atorvastatin, 6% with placebo; P = .26). The number of serious related adverse events was low and similar between groups. Conclusions and Relevance Among patients with lymphoma treated with anthracycline-based chemotherapy, atorvastatin reduced the incidence of cardiac dysfunction. This finding may support the use of atorvastatin in patients with lymphoma at high risk of cardiac dysfunction due to anthracycline use. Trial Registration ClinicalTrials.gov Identifier: NCT02943590
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lyy完成签到 ,获得积分10
刚刚
3秒前
myuniv完成签到,获得积分10
3秒前
专注鸵鸟完成签到,获得积分10
3秒前
专注之双完成签到,获得积分10
4秒前
Zircon完成签到 ,获得积分10
5秒前
Much完成签到 ,获得积分10
6秒前
6秒前
充电宝应助颠覆乾坤采纳,获得10
7秒前
8秒前
无花果应助pz采纳,获得10
8秒前
zheng完成签到 ,获得积分10
10秒前
量子星尘发布了新的文献求助10
11秒前
星辰大海应助荔枝采纳,获得10
11秒前
LJL发布了新的文献求助10
12秒前
meng发布了新的文献求助10
12秒前
无私的颤完成签到,获得积分10
12秒前
lucky完成签到 ,获得积分10
13秒前
Zel博博完成签到,获得积分10
13秒前
谷粱诗云完成签到,获得积分10
13秒前
yar应助myuniv采纳,获得10
13秒前
xc完成签到 ,获得积分10
14秒前
14秒前
干净的天与完成签到,获得积分10
14秒前
哈基米德应助毅诚菌采纳,获得10
16秒前
铁甲小杨完成签到,获得积分0
16秒前
17秒前
卡机了完成签到,获得积分10
18秒前
平淡绿柏完成签到,获得积分10
20秒前
架子猫发布了新的文献求助10
20秒前
20秒前
颠覆乾坤发布了新的文献求助10
21秒前
乔乔完成签到,获得积分10
22秒前
学术小白完成签到,获得积分10
22秒前
min完成签到,获得积分10
22秒前
22秒前
汉堡包应助slin_sjtu采纳,获得10
22秒前
czx完成签到,获得积分10
23秒前
szxnb666发布了新的文献求助30
23秒前
MRJJJJ完成签到,获得积分10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022